Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 15/20 | 0.59 |
| ▸ | PAK4 | O96013 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22054255 | 0.88 | PLK4 (0.67) | PLK4PAK4KMT2AMEN1HTT | |
| SCHEMBL25876200 | 0.82 | PLK4 (0.72) | PLK4PAK4KMT2AMEN1HTT | |
| SCHEMBL22054995 | 0.81 | PLK4 (0.57) | PLK4PAK4KMT2AMEN1HTT | |
| SCHEMBL175150 | 0.80 | PLK4 (0.59) | PLK4PAK4AURKANTRK1 | |
| SCHEMBL174987 | 0.80 | PLK4 (0.55) | PLK4PAK4KMT2AMEN1HTT | |
| SCHEMBL174966 | 0.78 | AURKA (0.53) | PLK4PAK4AURKA | |
| SCHEMBL25875763 | 0.78 | PLK4 (0.63) | PLK4PAK4KMT2AMEN1HTT | |
| SCHEMBL174285 | 0.77 | PLK4 (0.71) | PLK4PAK4NTRK1 | |
| SCHEMBL28978673 | 0.76 | PLK4 (0.54) | PLK4PAK4KMT2AMEN1HTT | |
| SCHEMBL174267 | 0.76 | PLK4 (0.47) | PLK4PAK4AURKANTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-14 | — | — | US | disclosed |
| EP-2611809-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030924-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK3, JAK2, JAK1 | PLK4 246/4885PAK4 784/4885KMT2A 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.